Pharmacogenetics and rational drug use around the world. (June 2011)

• Record Type: Journal Article
• Authors: Roederer, Mary W; Sanchez-Giron, Francisco; Kalideen, Kusha; Kudzi, William; McLeod, Howard L; Zhang, Wei
• Is Part Of: Pharmacogenomics. Volume 12:Number 6(2011)
• Page Start: 897
• Page End: 905
• Publication Date: 2011-06
• Subjects: China -- CYP2C19 -- CYP2C9 -- CYP2D6 -- Ghana -- medical decision-making -- Mexico -- N-acetyltransferase -- national formulary -- PGENI -- pharmacogenetics -- Pharmacogenetics for Every Nation Initiative -- pharmacovigilance -- South Africa -- WHO; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.11.17
• Languages: English
• ISSNs: 1462-2416

Abstract

The WHO embraces evidence-based medicine to formulate an essential medicines list (EML) considering disease prevalence, drug efficacy, drug safety and cost––effectiveness. The EML is used by developing countries to build a national formulary. As pharmacogenetics in developed countries evolves, the Pharmacogenetics for Every Nation Initiative (PGENI) convened with representatives from China, Mexico, Ghana and South Africa in August 2009 to evaluate the use of human pharmacogenetics to enhance global drug use policy. The diseases causing mortality, the lack of integration of pharmacovigilance at the national formulary level, the pharmacogenetics research agenda and pharmacogenetics clinician education did not differ greatly among the countries. While there are many unanswered questions, systematically incorporating pharmacogenetics at the national formulary level promises to improve global drug use.